"血亏五千多，千万别囤药。" 小红书上，李李晒出了自己数月前在互联网平台上购买的替尔泊肽注射液（穆峰达）40mg规格的订 单。订单显示，当时的成交价约3852元一支，她一共购买了两支，共花费了7704元。 然而现在，穆峰达却迎来了全线大降价，原本最贵的40mg规格现在最低仅需1320元，算下来，购买两 支的花费差不多是原来的三分之一，亏损约5060元。 李李的境遇并非孤例，她的帖子评论区里挤满了同病相怜的人们。有的抱怨自己之前打了一年多，花费 两三万元，虽然确实瘦了，但按现在的价怎么算怎么亏。还有不少原本想下单的消费者开始了观望，因 为不少人都在议论"明年1月份后恐怕价格会更低"。 而这一切，都是礼来、诺和诺德两大医药巨头"惹的祸"。 临近年末，礼来公司旗下的替尔泊肽正式纳入了新版国家医保目录。尽管得到明年1月1日正式进入医保 才能公布降价后的价格，但美团、京东健康等各大O2O平台已经提前开启了预售促销。而作为老对手， 诺和诺德的司美格鲁肽也参与了这场大降价。 不过消费者在得到实惠的同时，国产减肥药却"压力山大"了。 图/视觉中国 价格战开打 具体来看，替尔泊肽注射液（穆峰达）10mg规格预售到手价低至450 ...

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in its position in India’s fast-growing obesity drug market. Cheaper generic versions are expected to arrive as early as March next year, and the window to build brand loyalty is narrowing. In a notable push, the company has even partnered with well-known Bollywood actors in ...

Market Overview - The U.S. stock market is experiencing a consolidation phase after a year of significant breakthroughs, with the Dow closing at 48,378.13, down 83.80 points or 0.17% [6][12] - The S&P 500 settled at 6,902.11, off 3.63 points or 0.05%, and the NASDAQ ended at 23,460.62, slipping 13.73 points or 0.06% [6][12] Federal Reserve Insights - The Federal Reserve's December meeting minutes are anticipated to reveal divisions within the FOMC, following a 9-3 vote for the third consecutive interest rate cut, the highest dissent in six years [1] - The internal debate on inflation versus a cooling labor market will influence borrowing costs in 2026, with expectations for a pause until April [1] AI Sector Developments - The AI boom's "picks-and-shovels" phase is evolving, with semiconductor companies like Nvidia (NVDA) seeing a 39% stock rise, while Palantir (PLTR) and AMD surged 143% and 78%, respectively [2] - Analysts suggest future gains will come from companies effectively applying AI to enhance corporate earnings, shifting focus towards software and enterprise applications [2] Pharmaceutical Sector Highlights - Eli Lilly (LLY) achieved a historic $1 trillion market cap, with a 40% gain in 2025 driven by the success of Zepbound, and plans to launch orforglipron in Q2 2026 [3] - Johnson & Johnson (JNJ) matched Lilly's gains through a medtech turnaround, preparing to submit its Ottava surgical robot for FDA approval in early 2026 [3] Stock Performance - Merck (MRK) is emerging as a top pick for 2026, upgraded to "outperform" by BMO Capital Markets due to its strengthening pipeline ahead of the 2028 Keytruda patent cliff [4][12] - Ekso Bionics (EKSO) saw a significant breakout, rising 102.08% to $11.03, following news of Applied Digital's plans to spin out its cloud business [7] - Cemtrex, Inc. (CETX) reported a return to operating profitability with $76.5 million in revenue, a 14% year-over-year increase, leading to a 22.99% stock rise [11] Precious Metals Movement - Silver prices surged to $77.3285 per ounce, up $5.1885 or 7.19%, reflecting increased safe-haven demand amid equity market reassessments [9][10] - Gold prices climbed to $4,366.76 per ounce, gaining $34.78 or 0.80%, indicating continued investor demand for stability amid market volatility [10]

Core Insights - Amgen is developing MariTide, a late-stage obesity candidate, to compete with Eli Lilly and Novo Nordisk in the GLP-1 therapy market [1] - MariTide's long-acting profile allows for monthly or less frequent dosing, potentially improving patient adherence compared to weekly injectable options [2] - The drug is being evaluated in pivotal studies for obesity and other cardiometabolic conditions, with strong enrollment interest [3][4] Group 1: Product Development and Market Position - MariTide is part of Amgen's MARITIME phase III program, focusing on obesity and related cardiometabolic indications [1][3] - The drug has shown predictable and sustained weight loss in earlier studies, positioning it as a convenient long-term treatment option [2] - Enrollment for MARITIME-1 and MARITIME-2 studies has been completed with approximately 5,000 patients participating [3] Group 2: Competitive Landscape - Novo Nordisk has received FDA approval for an oral version of Wegovy, enhancing competition in the obesity treatment market [5] - Eli Lilly is also advancing its oral obesity candidate, orforglipron, with a potential launch next year [6] - Both market leaders continue to invest in next-generation therapies, indicating a robust competitive environment [7][8] Group 3: Financial Performance and Valuation - Amgen's shares have outperformed the industry year to date, reflecting positive market sentiment [9] - The company is trading at a P/E ratio of 15.20, which is below the industry average of 17.56, indicating a potential valuation opportunity [12] - EPS estimates for 2025 and 2026 have increased in the past 60 days, suggesting positive growth expectations [14]

4年前，诺和诺德的长效GLP-1药物司美格鲁肽上市后凭借超强的减重效果一炮而红。 自此之后，诺和诺德也在2023年超越法国奢侈品巨头LVMH，一举摘得欧洲市值最高的上市公司王座。 但随着礼来推出了减重效果更强的GLP-1/GIP双靶点减肥替尔泊肽后，诺和诺德已经日益落寞，市值从去年7月迄今蒸发了超过6成。 尽管替尔泊肽仍有一定的独家地位，但终端价格似乎正在渠道的竞争下有些扛不住了。 更大互联网平台之间，已然掀起了一场针对减肥神药的无声价格战。 日前，美团买药补贴下的替尔泊肽10mg规格预售到手价低至450元，低于阿里、京东自营平台数十元。 在这场一触即发的价格战中，固然有替尔泊肽近期进入医保目录后大幅降价对院外市场价格体系的冲击，但更为关键的因素或还是指向了GLP-1 赛道的内卷。 随着替尔泊肽价格的走低，后续国产GLP-1药物正在面临更为严酷的竞争。 首当其冲的是信达生物，其GLP-1/GCGR双靶点药物玛仕度肽（2mg*2）目前价格仍显著高出替尔泊肽百元左右。 若不采取降价，玛仕度肽后续市场开拓难言乐观。 同质化玩家要面临的挑战更为激烈。据不完全统计，目前国内已有不少于10家药企正在推进司美格鲁肽的上市申 ...

2025.12. 30 本文字数：2062，阅读时长大约4分钟 第一财经记者从礼来方面了解到，所有关于药品价格的信息，以医保局及医院的官方挂网价为准。替 尔泊肽纳入医保后的价格也将于1月1日正式公布。 多家三甲医院内分泌科及减重中心的专家告诉第一财经记者，替尔泊肽进医保后的价格"大幅跳水"并 不令人意外。"减重药的市场竞争肯定是越来越卷的，很快就'白菜价'了。"一位内分泌科主任对第一 财经记者表示。同时称，随着减重药价格的下降，市场也可能迎来"以价换量"的新格局，更多肥胖患 者将能负担得起曾经被认为"高不可攀"的减重药。 今年前三季度，替尔泊肽为礼来贡献了销售总额的半壁江山，并助其在11月成为全球首个市值突破1 万亿美元的医药公司。 作者 | 第一财经 钱童心 基于大量的用户数据，互联网电商平台正在成为减重药企重要的合作伙伴。第一财经记者刚刚在某互 联网平台上查询相关减重药的信息，就立马收到短信广告："别让肚腩负担毁了旅行，露腰自由自信 站C位！"后面附有某国内减重药厂商的产品购买链接。 这就是减重药市场的竞争现状。跨国巨头也在积极投身这场难以避免的"价格战"。礼来的减重药替尔 泊肽纳入医保后，价格也将"大跳 ...

第一财经记者注意到，在南京鼓楼医院公众号上，该院减重代谢中心称，自明年1月1日起，替尔泊肽 将"大降价"，具体价格为2.5mg*4次324.1元；5.0mg*4次551元；7.5mg*4次751元；10mg*4次936.7元。 以上剂量为每周一次注射。 药企对待这些减重药物的态度，就像在告诉消费者"你现在可以像买一个智能手机那样去买药。"互联网 医疗平台也成为减重药厂商的下一个"竞技场"。 基于大量的用户数据，互联网电商平台正在成为减重药企重要的合作伙伴。第一财经记者刚刚在某互联 网平台上查询相关减重药的信息，就立马收到短信广告："别让肚腩负担毁了旅行，露腰自由自信站C 位！"后面附有某国内减重药厂商的产品购买链接。 这就是减重药市场的竞争现状。跨国巨头也在积极投身这场难以避免的"价格战"。礼来的减重药替尔泊 肽纳入医保后，价格也将"大跳水"。 礼来减重药价格"大跳水" 明年1月1日起，礼来公司的重磅减重药替尔泊肽（商品名：穆峰达）即将纳入医保。近日，已有医院相 关科室公开了1月1日起替尔泊肽的价格。 与此同时，诺和诺德的重磅减重药司美格鲁肽的价格预计也将出现下调。根据四川省药械招采中心近日 公示的一批药品降 ...

导语 替尔泊肽的研发厂家是礼来，替尔泊肽的降糖适应证将于明年1月1日正式纳入医保报销范围。礼来方面尚未披露替尔泊肽的具体医保支付价。 行业竞争日趋激烈。两折、五折，进口减肥药比拼降价，行业正在告别超额利润 曾经一支难求的进口GLP-1减肥药，现在已进入降价通道了。 近日，在云南省药品集中采购平台和四川省药械招标采购服务中心上，都出现了进口减肥药司美格鲁肽（商品名：诺和盈）注射液降价信息。 此次涉及的是司美格鲁肽这两种规格产品，即"2.27mg/ml,3ml"和"3.2mg/ml,3ml"，原来每支价格分别是1893.67元、2463元，降价后变为987.48元、1284.36 元，相当于是原来价格一半。 这是厂家诺和诺德主动调价后的结果。一些电商平台，也在跟进调整相关产品价格。 诺和诺德方面对第一财经记者表示，此次报销方案的调整，将进一步切实帮助患者减轻治疗负担，助力提升治疗依从性。 几乎在同一时间，一些电商平台也出现了另外一款进口GLP减肥药替尔泊肽降价信息。 不过，一些电商平台已在启动替尔泊肽在院外市场的降价预售活动，这里面也涉及减肥适应证。 肥胖是一种复杂的慢性疾病，是心血管疾病、2型糖尿病及部分癌症等 ...

Core Viewpoint - The oral weight loss drug sector is entering a critical commercialization phase, with significant regulatory approvals and partnerships indicating strong market potential and demand for innovative treatments [4][5][6]. Group 1: Recent Developments in Oral Weight Loss Drugs - On December 23, 2025, the FDA approved Novo Nordisk's oral semaglutide for chronic weight management, marking a significant milestone for oral GLP-1 peptides [4]. - Eli Lilly's management anticipates that the oral small molecule weight loss drug orforglipron will likely receive approval by March 2026, potentially becoming the second approved oral weight loss medication [4]. - Recent data releases include Structure's report on aleniglipron, which showed a 11.3% weight loss in the 120mg dose group and 15.3% in the 240mg dose group after 36 weeks [4]. Group 2: Industry Partnerships and Strategic Moves - On December 9, 2025, Pfizer announced an exclusive collaboration with YaoPharma for the oral small molecule GLP-1R agonist YP05002, involving a $150 million upfront payment and up to $1.935 billion in milestones, indicating strong interest from multinational pharmaceutical companies in oral weight loss products [5]. - Shijiazhuang Pharmaceutical Innovation announced the establishment of a joint venture focused on innovative metabolic drug development, highlighting the recognition of the significant value in GLP-1 related metabolic disease medications [6]. Group 3: Market Trends and Valuation Recovery - The pharmaceutical and biotechnology sector has seen a recovery in valuation, with the PE ratio stabilizing and increasing since Q1 2025, driven by macroeconomic conditions and supportive policies for innovative drugs [7]. - The global trend of returning to a rate-cutting environment, alongside increasing healthcare spending due to aging populations, is expected to expand the global demand for pharmaceuticals, particularly benefiting China's pharmaceutical industry [8]. Group 4: Investment Themes in Innovation - The investment focus is categorized into three phases: "0→1" for breakthrough technologies in innovative drugs, "1→10" for clinical validation of high-quality domestic innovative drugs, and "10→100" for leveraging China's efficiency in the pharmaceutical supply chain [9]. - The acceleration of business development (BD) for innovative drugs and the rise of high-end medical devices and consumables are seen as promising investment opportunities [9].

受大宗商品巨幅波动引发的紧张情绪推动，昨夜今晨，美股三大指数集体收跌。 截至收盘，标普500指数跌0.35%，报6905.74点；纳斯达克综合指数跌0.5%，报23474.35点；道琼斯工业平均指数跌0.51%，报48461.93点。 （标普500指数日线图，来源：TradingView） 本周也是经济日程相当清淡的一周，投资者将在周二（北京时间周三凌晨）迎来美联储12月会议纪要，下一个重要日程就是迎接元旦假期的到来。 作为日内全球市场的焦点，这一轮金属上涨狂潮的"带头大哥"白银日内巨震，Comex白银期货创出每盎司82美元新高后跳水至71.6美元，黄金、铂金、钯金 等品种也携手下挫。矿业板块集体下跌，First Majestic Silver跌4.13%、纽曼矿业跌5.64%，锂矿巨头美国雅宝也跌3.62%。 | < W | COMEX白银 | | | | | | --- | --- | --- | --- | --- | --- | | | SI.CMX | | | | | | 71.640 | | 昨结 | 77.196 总手 | | | | -5.556 | -7.20% 开盘 | | 80.000 ...